Evidence-based liver chemistry monitoring in drug development

Pharmaceutical Medicine

Volumn 23, Issue 3, 2009, Pages 149-158

  Hunt, Christine M ^a   Forster, John K ^b   Papay, Julie I ^a   Stirnadel, Heide A ^b  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BENOXAPROFEN; BILIRUBIN; BROMFENAC; TIENILIC ACID; TROGLITAZONE; TROVAFLOXACIN;

ARTICLE; BLOOD CHEMISTRY; CLINICAL TRIAL; DRUG MARKETING; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HEALTH PROGRAM; HUMAN; INCIDENCE; JAUNDICE; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 69249093416     PISSN: 11782595     EISSN: 11791993     Source Type: Journal    
DOI: 10.1007/bf03256763     Document Type: Article

References (47)

1. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349 (5): 474-485
2. Ostapowicz G, Fontana RJ, Schiodt FV, et al., Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947-954
3. Bakke OM, Mannochia M, de Abajo F, et al. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 to 1983: a regulatory perspective. Clin Pharmacol Ther 1995; 58: 108-117
4. Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002. Arch Intern Med 2005; 165: 1363-1369
5. U.S. Food and Drug Administration Center for Drug Evaluation and Research. Drug-induced liver toxicity [online]. Available from URL: http:// www.fda.gov/cder/livertox/default.htm [Accessed 2008 Oct 17]
6. U.S. Food and Drug Administration. World Health Organization graded laboratory tables [online]. Available from URL: http://www.fda.gov/cder/ cancer/toxicityframe.htm [Accessed 2008 Oct 17]
7. Temple R. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006; 15: 241-243
8. Danan G, Benichou C. Causality assessment of adverse reactions to drugs: I. A novel method based on the conclusions of international consensus meetings. Application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-1330
9. Kaplowitz N. Rules and laws of drug hepatotoxicity. Pharmacoepidemiol Drug Saf 2006; 15: 231-233
10. Fontana RJ, Timothy M, McCashland TM, et al. Acute Liver failure associated with prolonged use of bromfenac leading to liver transplantation. Liver Transpl Surg 1999; 5: 480-484
11. Zimmerman HJ. Hepatotoxicity. 2nd ed. Philadelphia (PA): Lippincott Williams & Wilkins, 1999
12. Manier JW, Chang WW, Kirschner JP, et al. Hepatotoxicity associated with ticrynafen: a uricosuric diuretic. Am J Gastroenterol 1982; 77 (6): 401-404
13. Zimmerman HJ, Lewis JH, Ishak KG, et al. Ticrynafen-associated hepatic injury: analysis of 340 cases. Hepatology 1984; 4 (2) 315-323 (Pubitemid 14131442)
14. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002; 6: 755-774
15. Graham DJ, Green L, Senior JR, et al. Troglitazone-induced liver failure: a case study. Am J Med 2003; 114: 299-306 (Pubitemid 36398076)
16. Scheen AJ. Hepatotoxicity with thiazolidinediones: is it a class effect. Drug Saf 2001; 24 (12): 873-888
17. Kuramoto K, Shimizu N, Toda G. Liver dysfunction associated with troglitazone (Noscal) [in Japanese]. Rinsho Iyaku 1998; 14: 461-466
18. Slavin DE, Schlinchting CL, Freston JW. Rating the severity of the medical consequences of drug-induced injury. Regul Toxicol Pharmacol 2005; 43: 134-140 (Pubitemid 41427806)
19. Benoxaprofen [editorial]. BMJ (Clin Res Ed) 1982; 285 (6340): 459-460
20. Eason CT, Bonner FW, Parke DV. The importance of pharmacokinetic and receptor studies in drug safety evaluation. Regul Tox Pharm 1990; 11: 288-307 (Pubitemid 20325470)
21. Dyer C. Benoxaprofen case makes legal history. BMJ 1987; 295: 39-40 (Pubitemid 17089999)
22. Prescott LF. Effects of non-narcotic analgesics on the liver. Drugs 1987; 32 Suppl. 4: 129-147
23. Zimmerman HJ, Lewis JH. Drug induced cholestasis. Med Toxicol 1987; 2: 112-160
24. Meadows M. Serious liver injury: leading reason for drug removals, restrictions. FDA Consum 2001 May-Jun; 35 (3): 8-9 (Pubitemid 33707731)
25. U.S. Food and Drug Administration. Trovafloxacin FDA medical review [online]. Available from URL: http://www.fda.gov/cder/foi/nda/97/020760a- medr-P7.pdf [Accessed 24 Jan 2009]
26. Mandell LA, Ball P, Tillotson G. Antimicrobial safety and tolerability: differences and dilemmas. Clin Infect Dis 2001; 32 Suppl. 1: S72-9 (Pubitemid 32506749)
27. de Abajo FJ, Montero D, Madurga M, et al. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004; 58 (1): 71-80 (Pubitemid 38901470)
28. Bjornsson E, Olsson R. Outcome and prognostic markers in severe druginduced liver disease. Hepatology 2005; 42 (2): 481-489 (Pubitemid 41061102)
29. Andrade RJ, Lucena MI, Fernández MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-521
30. Conforti A, Leone R, Ghiotto E, et al. Spontaneous reporting of drug-related hepatic reactions from two Italian regions (Lombardy and Veneto). Dig Liver Dis 2000; 32: 716-723
31. Becker S. Liver toxicity in epidemiological cohorts. Clin Infect Dis 2004; 38 Suppl. 2: S49-55
32. U.S. Food and Drug Administration. FDA guidance on safety testing of drug metabolites [online]. Available from URL: http://www.fda.gov/cder/livertox/ default.htm [Accessed 2008 Oct 17]
33. Thompson NP, Caplin ME, Hamilton SH, et al. Anti-tuberculosis medication and the liver: dangers and recommendations in management. Eur Respir J 1995; 8: 1384-1388
34. Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 2006; 43: 618-631
35. Watkins PB, Zimmerman HJ, Knapp MJ, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271: 992-998 (Pubitemid 24099919)
36. Hammel P, Larrey D, Bernuau J, et al. Acute hepatitis after tetrahydroaminoacridine administration for Alzheimer's disease. J Clin Gastroenterol 1990; 12: 329-331 (Pubitemid 20207698)
37. Blackard WG, Sood GK, Crowe DR, et al. Tacrine: a cause of fatal hepatotoxicity? J Clin Gastroenterol 1998; 26 (1): 57-59
38. Mansouri A, Haouzi D, Descatoire V, et al. Tacrine inhibits topoisomerases and DNA synthesis to cause mitochondrial DNA depletion and apoptosis in mouse liver. Hepatology 2003; 38: 715-725 (Pubitemid 37052158)
39. Dyken JA, Marroquin LD, Will Y. Strategies to reduce late-stage attrition due to mitochondrial toxicity. Exp Rev Mol Diagn 2007; 7 (2): 161-175 (Pubitemid 46513443)
40. Ganey PE, Luyendyk JP, Maddox JF, et al. Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. Chem Biol Interact 2004; 150: 35-51
41. ClinicalTrials.gov. Drug-induced liver injury (DILN) network retrospective (ILIAD) [ClinicalTrials.gov identifier no. NCT00360646]. US National Institutes of Health,ClinicalTrials.gov [online]. Available fromURL: http://clinical trials.gov/ [Accessed 2008 Oct 17]
42. ClinicalTrials.gov. A multi-center trial to study acute liver failure in adults (ALFSG) [ClinicalTrials.gov identifier no. NCT00518440]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http:// clinicaltrials.gov/ [Accessed 2008 Oct 17]
43. International SAE Consortium homepage [online]. Available from URL: http://www.saeconsortium.org/index.php [Accessed 2008 Oct 17]
44. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005; 4: 489-499
45. Charles EC, Olson KL, Sandhoff BG. Evaluation of cases of severe statinrelated transaminitis within a large health maintenance organization. Am J Med 2005; 118: 618-624
46. Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut 1999; 44: 731-735
47. Weil JG, Bains C, Linke A, et al. Background incidence of liver chemistry abnormalities in a clinical trial population without underlying liver disease. Regul Toxicol Pharmacol 2008; 52: 85-88